Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Patients with obesity, with or without diabetes, lose up to 20% body weight and show A1c reductions with the novel agent maridebart cafraglutide, though nearly all experience GI side effects.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...